# Compare AOD-9604, Tesamorelin and MOTS-c — Raw Wholesale Peptides > Side-by-side comparison of three Metabolic & Weight Research peptides — AOD-9604, Tesamorelin, and MOTS-c — across peptide class, most-studied model, evidence base, administration studied, regulatory status, and key caution. Where the three diverge on mechanism, species, evidence strength, regulatory standing, and the single biggest caveat each one carries. ## The short version This page lines up [AOD-9604](/aod-9604), [Tesamorelin](/tesamorelin), and [MOTS-c](/mots-c) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is simple. All three are studied in the context of fat metabolism or metabolic regulation, but they are at very different stages: Tesamorelin has the most human evidence and a narrow FDA approval, AOD-9604 completed a human obesity programme and failed to meet its primary endpoint, and MOTS-c has no completed human efficacy trials. None is an approved medicine for general fat loss or metabolic optimization. ## The comparison matrix | Dimension | AOD-9604 | Tesamorelin | MOTS-c | | --- | --- | --- | --- | | Peptide class | Synthetic hGH C-terminal fragment (16 aa) | Synthetic GHRH analogue (44 aa) | Mitochondrial-encoded peptide (16 aa) | | Most-studied in | Fat metabolism, adipocyte lipolysis (rodent) | Visceral fat in HIV-associated lipodystrophy (human RCT) | Skeletal muscle glucose uptake, AMPK (mouse) | | Evidence base (model) | Rodent + ~900-subject human programme (failed primary endpoint) [3] | HIV RCT programme; meta-analysis of 5 RCTs [8] | Mouse and cell only; no human efficacy trials [15] | | Administration studied | Oral (human trials); IP (rodent) [2][3] | SC injection 2 mg/day (human trials) [10][12] | IP injection (mouse); no human PK published [16] | | Regulatory / WADA status | Not approved; WADA S2 prohibited; 503A status under review | FDA-approved (NDA 022505, HIV lipodystrophy only); WADA S2 prohibited | Not approved; WADA metabolic-modulator prohibition | | Key caution | Pivotal human trials did not meet weight-loss endpoint [3] | Approval is HIV-specific; off-label use is uninvestigated in RCTs | No human efficacy trials; no validated human PK | ## Peptide class All three are 16-44 amino acids, but their origins and designs are entirely different. AOD-9604 is an engineered fragment — the C-terminal lipolytic portion of human growth hormone, cut away and modified to remove GHR binding [6]. Tesamorelin is a lengthened and stabilized analogue of the natural GHRH signal that prompts pituitary GH release, bearing a DPP-IV-resistant N-terminal modification [12]. MOTS-c is in a different category entirely: it is not derived from a nuclear-encoded human protein but is transcribed from the mitochondrial genome, making it the only signaling peptide on this desk with a non-nuclear genetic origin [15]. ## Most-studied in Each peptide has a distinct experimental home. AOD-9604 is most studied in rodent adiposity models — obese mice, beta-3 adrenergic signaling in white adipose tissue, and acetyl-CoA carboxylase inhibition in adipocyte and hepatocyte preparations [4][7]. Tesamorelin is most studied in HIV-infected adults on antiretroviral therapy, where its VAT-reducing effect is well-replicated across multiple controlled trials [8][12]. MOTS-c is most studied in mouse skeletal muscle and in aged mice, where it demonstrates exercise-mimetic effects on physical performance, grip strength, and glucose handling [16]. ## Evidence base (model) This is where the three genuinely separate in important ways. Tesamorelin has the most human data — a 52-week RCT, a JAMA publication, and a 2026 meta-analysis of five RCTs [8][10][12] — but that evidence is in one population: HIV-infected adults with lipodystrophy. AOD-9604 has the most completed human trials in a general population (roughly 900 obese adults across about six studies), but those trials failed to demonstrate statistically significant weight loss [3]. MOTS-c has the weakest human footing: the human data are a single observational biomarker cohort study in hemodialysis patients, not an efficacy trial [14]; all metabolic and performance benefits were demonstrated in mice [16]. ## Administration studied Routes are dictated by the research questions. AOD-9604 was developed as an oral compound and was studied orally across its human clinical programme; preclinical work used intraperitoneal injection [2][3]. Tesamorelin is studied as a daily subcutaneous injection of 2 mg, which is how the approved clinical formulation is administered [10][12]. MOTS-c's human pharmacokinetics have not been published in the peer-reviewed literature; rodent work used intraperitoneal injection, and there is no validated subcutaneous bioavailability or dose-response for humans [16]. ## Regulatory / WADA status The three have different regulatory profiles that matter for any reader. Tesamorelin holds an FDA approval (NDA 022505, November 2010) for HIV-associated lipodystrophy — a real, narrow, regulated indication [9]. AOD-9604 is not approved for any indication by any major regulator; its 503A compounding eligibility is under review following an FDA Pharmacy Compounding Advisory Committee meeting in December 2024 [3]. MOTS-c is not approved by the FDA for any use. For WADA purposes, all three fall within prohibited categories: tesamorelin and AOD-9604 are explicitly S2 (peptide hormones, growth factors) prohibited at all times; MOTS-c is treated as a prohibited metabolic modulator by anti-doping authorities. ## Key caution Each peptide carries a defining caveat. For AOD-9604 it is the direct translation failure: a coherent rodent mechanism did not produce weight loss in approximately 900 human subjects, and the programme was discontinued [3]. For Tesamorelin it is specificity: the approval and the RCT evidence are HIV-lipodystrophy specific, and off-label use in non-HIV populations has not been validated in controlled trials [9]. For MOTS-c it is absence: mechanistic precision in cells and mice, no completed human efficacy trials, and no published human pharmacokinetics [15]. Reading them together, the desk's lesson is the field's lesson: mechanistic clarity in animals does not guarantee human benefit, and even regulatory approval is narrower than popular coverage suggests. --- A precision literature digest — what the studies actually show, in the species they actually studied.